SYGNIS, BioCat Sign Non-Exclusive Distribution Agreement
News Dec 09, 2014
SYGNIS AG has announced that it has signed an initial distribution agreement for its first proprietary product with German BioCat GmbH.
With this agreement, SYGNIS grants BioCat non-exclusive rights to promote, market, sell, and support TruePrime™ Single Cell WGA kit for the DNA amplification of single cells for next generation sequencing (NGS) applications.
TruePrime™ Single Cell WGA kit will be the first in a row of products of SYGNIS’ TruePrime™ product family for the amplification of various DNA or RNA species for a multitude of applications and is expected to be launched in January 2015.
As a highly specialized solution provider, BioCat is offering a wide range of high-quality research reagents as well as cutting-edge technologies in the fields of genomics, proteomics, and cell biology to customers all over Europe.
“We are very pleased about this distribution agreement for our first proprietary product with a strong and important partner like BioCat. With its wide customer network focused on molecular biology and its unparalleled logistics, BioCat provides the ability to leverage the benefits of this new technology to researchers working in the fast growing field of NGS,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Having TruePrime™ Single Cell WGA kit now widely available in Europe, is a major achievement in our new product and commercialization strategy. In addition, signing such a contract prior to product launch, proves the attractiveness of TruePrime™ Single Cell WGA kit and shows the faith and confidence of market expert BioCat in our product.”
“We’re excited about adding SYGNIS’ products to our portfolio of innovative products and technologies for researchers working in the molecular biology field”, Dr. Michael Ehret, CEO of BioCat GmbH added. “The superior features of TruePrime™ make it highly attractive for use in areas such as human genetics, oncology, or pathology where researchers need to obtain biological information from the smallest amounts of samples. This agreement will provide us with a product to more effectively address the fast growing market of next generation sequencing.”